Stock Analiz

Alnylam Pharmaceuticals, Inc. (ALNY) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Alnylam Pharmaceuticals’s revenue went from $47M in fiscal 2016 to $3.7B in fiscal 2025, growth of about 62.4% a year.

Net income in fiscal 2025 was $314M, a net margin of 8.4%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $5.0B and net income $2.6B.

Free cash flow was $465M in fiscal 2025 and positive in 2 of the 10 years shown.

The diluted share count rose 57% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $47M162017: $90M172018: $75M182019: $220M192020: $493M202021: $844M212022: $1.0B222023: $1.8B232024: $2.2B242025: $3.7B25$3.7B
Net income
2016: -$410M162017: -$491M172018: -$761M182019: -$886M192020: -$858M202021: -$853M212022: -$1.1B222023: -$440M232024: -$278M242025: $314M25$314M
Free cash flow
2016: -$372M162017: -$487M172018: -$690M182019: -$419M192020: -$685M202021: -$718M212022: -$613M222023: $42M232024: -$43M242025: $465M25$465M
EPS (diluted)
2016: $-4.79162017: $-5.42172018: $-7.57182019: $-8.11192020: $-7.46202021: $-7.20212022: $-9.30222023: $-3.52232024: $-2.18242025: $2.3325$2.33

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$5.0B$3.7B$2.2B$1.8B$1.0B$844M$493M$220M$75M$90M$47M
Gross profit$3.9B$3.0B$1.9B$1.6B$897M$729M$419M$195M$73M$90M—
Operating income$978M$502M-$177M-$282M-$785M-$709M-$828M-$939M-$815M-$500M-$425M
Net income$2.6B$314M-$278M-$440M-$1.1B-$853M-$858M-$886M-$761M-$491M-$410M
EPS (diluted)$19.24$2.33$-2.18$-3.52$-9.30$-7.20$-7.46$-8.11$-7.57$-5.42$-4.79
R&D$1.6B$1.3B$1.1B$1.0B$883M$792M$655M$655M$505M$391M$382M
Revenue growth—+65.2%+23.0%+76.2%+22.9%+71.3%+124.3%+193.4%−16.7%+90.7%—

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$956M$524M-$8M$104M-$541M-$642M-$615M-$278M-$563M-$383M-$308M
Capital spending-$150M-$59M-$34M-$62M-$72M-$76M-$70M-$140M-$127M-$104M-$65M
Free cash flow$806M$465M-$43M$42M-$613M-$718M-$685M-$419M-$690M-$487M-$372M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$308M$348M$272M$222M$231M$166M$140M$175M$158M$93M$76M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$2.9B$2.7B$2.4B$2.2B$2.4B$1.8B$1.5B$1.1B$1.7B$618M
Debt—$1.3B$1.3B$1.3B$1.3B$322M$521M$304M$30M$30M$150M
Equity—$789M$67M-$221M-$158M$588M$1.0B$1.4B$1.3B$1.8B$920M
Total assets—$5.0B$4.2B$3.8B$3.5B$3.6B$3.4B$2.4B$1.6B$2.0B$1.3B
Shares (diluted)138M135M128M125M122M118M115M109M101M91M86M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin77.4%81.8%86.4%85.3%86.5%86.4%85.0%88.6%97.6%100.0%—
Operating margin19.5%13.5%-7.9%-15.4%-75.7%-83.9%-168.1%-427.5%-1087.6%-556.2%-900.3%
Net margin52.8%8.5%-12.4%-24.1%-109.0%-101.0%-174.2%-403.2%-1016.6%-546.0%-869.6%
FCF margin16.1%12.5%-1.9%2.3%-59.1%-85.0%-139.1%-190.5%-920.5%-541.6%-789.4%
ROIC—23.5%-9.6%-20.5%-53.4%-61.5%-42.6%-42.6%-48.3%-27.8%-39.7%
ROE—39.8%-414.6%199.5%714.9%-145.0%-84.5%-61.6%-58.5%-27.8%-44.6%

Frequently asked questions

What is Alnylam Pharmaceuticals’s annual revenue?

$3.7B in fiscal 2025 and $5.0B over the twelve months to September 30, 2026.

How much profit does Alnylam Pharmaceuticals make?

Net income was $314M in fiscal 2025 (net margin 8.4%).

Is Alnylam Pharmaceuticals’s revenue growing?

Yes: revenue rose 65.2% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.